

# Chrysoula Vraka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8169959/publications.pdf>

Version: 2024-02-01

39  
papers

483  
citations

840585

11  
h-index

794469

19  
g-index

43  
all docs

43  
docs citations

43  
times ranked

770  
citing authors

#	ARTICLE	IF	CITATIONS
1	Simultaneous radiomethylation of [ <sup>11</sup> C]harmine and [ <sup>11</sup> C]DASB and kinetic modeling approach for serotonergic brain imaging in the same individual. <i>Scientific Reports</i> , 2022, 12, 3283.	1.6	0
2	A Microdosing Study with <sup>99m</sup> Tc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 360-365.	2.8	20
3	Prediction of response and survival after standardized treatment with 7400ÂMBq <sup>177</sup> Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1650-1657.	3.3	21
4	Radiolabeled HER2-directed exosomes exhibit improved cell targeting and specificity. <i>Nanomedicine</i> , 2021, 16, 553-567.	1.7	5
5	Diagnostic Role of PET/CT Tracers in the Detection and Localization of Tumours Responsible for Ectopic Cushing's Syndrome. <i>Anticancer Research</i> , 2021, 41, 2477-2484.	0.5	3
6	Response and Toxicity to the Second Course of 3 Cycles of <sup>177</sup> Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 2489.	1.7	6
7	If It Works, Don't Touch It? A Cell-Based Approach to Studying 2-[ <sup>18</sup> F]FDG Metabolism. <i>Pharmaceuticals</i> , 2021, 14, 910.	1.7	2
8	Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 3692-3704.	0.9	5
9	High-dose testosterone treatment reduces monoamine oxidase A levels in the human brain: A preliminary report. <i>Psychoneuroendocrinology</i> , 2021, 133, 105381.	1.3	11
10	Discovery of melanin-concentrating hormone receptor 1 in brown adipose tissue. <i>Annals of the New York Academy of Sciences</i> , 2021, 1494, 70-86.	1.8	2
11	First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)- <sup>11</sup> C-Me-NB1. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262427.	2.8	14
12	Unexpected scaffold rearrangement product of pirenzepine found in commercial samples. <i>Scientific Reports</i> , 2021, 11, 23397.	1.6	1
13	Enhanced arecoline derivatives as muscarinic acetylcholine receptor M1 ligands for potential application as PET radiotracers. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112623.	2.6	8
14	Synthesis, Biological, and Computational Evaluation of Antagonistic, Chiral Hydrobenzoin Esters of Arecaidine Targeting mAChR M1. <i>Pharmaceuticals</i> , 2020, 13, 437.	1.7	6
15	SNAPshots of the MCHR1: a Comparison Between the PET-Tracers [ <sup>18</sup> F]FE@SNAP and [ <sup>11</sup> C]SNAP-7941. <i>Molecular Imaging and Biology</i> , 2019, 21, 257-268.	1.3	5
16	Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 172.	1.4	6
17	Synthesis and in vitro evaluation of new translocator protein ligands designed for positron emission tomography. <i>Future Medicinal Chemistry</i> , 2019, 11, 539-550.	1.1	3
18	Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. <i>European Neuropsychopharmacology</i> , 2019, 29, 711-719.	0.3	11

#	ARTICLE	IF	CITATIONS
19	(R)-[18F]NEBIFQUINIDE: A promising new PET tracer for TSPO imaging. <i>European Journal of Medicinal Chemistry</i> , 2019, 176, 410-418.	2.6	14
20	Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [ <sup>11</sup> C]SNAP-7941. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	2
21	Assessment of sympathetic reinnervation after cardiac transplantation using hybrid cardiac PET/MRI: A pilot study. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1326-1335.	1.9	9
22	The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. <i>Brain Stimulation</i> , 2019, 12, 714-723.	0.7	24
23	Optimization of the Automated Synthesis of [ <sup>11</sup> C]mHED Administered and Apparent Molar Activities. <i>Pharmaceuticals</i> , 2019, 12, 12.	1.7	1
24	Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. <i>Cerebral Cortex</i> , 2019, 29, 372-382.	1.6	12
25	Pitfalls and solutions of the fully-automated radiosynthesis of [ <sup>11</sup> C]metoclopramide. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 31.	1.8	7
26	Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. <i>Brain Structure and Function</i> , 2018, 223, 1369-1378.	1.2	34
27	A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. <i>Nuclear Medicine and Biology</i> , 2018, 60, 29-36.	0.3	5
28	Expanding LogP: Present possibilities. <i>Nuclear Medicine and Biology</i> , 2018, 58, 20-32.	0.3	17
29	Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. <i>Translational Psychiatry</i> , 2018, 8, 198.	2.4	22
30	Molar activity – The keystone in <sup>11</sup> C-radiochemistry: An explorative study using the gas phase method. <i>Nuclear Medicine and Biology</i> , 2018, 67, 21-26.	0.3	4
31	L-[S-methyl- <sup>11</sup> C]methionine – An example of radiosynthetic optimization. <i>Applied Radiation and Isotopes</i> , 2018, 141, 107-111.	0.7	3
32	An Overview of PET Radiochemistry, Part 1: The Covalent Labels <sup>18</sup> F, <sup>11</sup> C, and <sup>13</sup> N. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1350-1354.	2.8	26
33	Log P , a yesterday's value?. <i>Nuclear Medicine and Biology</i> , 2017, 50, 1-10.	0.3	62
34	Reconsider logP!. <i>Nuclear Medicine and Biology</i> , 2017, 54, 42.	0.3	3
35	Quantification of Task-Specific Glucose Metabolism with Constant Infusion of <sup>18</sup> F-FDG. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1933-1940.	2.8	64
36	Development of a Novel Nonpeptidic <sup>18</sup> F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1800-1817.	2.9	17

#	ARTICLE	IF	CITATIONS
37	Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [11C]ME@HAPTHI. EJMNM Research, 2015, 5, 113.	1.1	11
38	Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4490-4495.	1.0	9
39	Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [11C]IPCIT and [18F]FE@IPCIT. Bioorganic and Medicinal Chemistry, 2013, 21, 7562-7569.	1.4	8